Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


We employ our advanced, specialised process to create targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
P67812

UPID:
SC11A_HUMAN

ALTERNATIVE NAMES:
Endopeptidase SP18; Microsomal signal peptidase 18 kDa subunit; SEC11 homolog A; SEC11-like protein 1; SPC18

ALTERNATIVE UPACC:
P67812; B2RAD7; B4DUL4; H0YK72; H0YK83; O75957; P21378; Q53FQ8

BACKGROUND:
The protein SEC11A, also known as Endopeptidase SP18, is a key component of the signal peptidase complex, responsible for the cleavage of signal peptides from nascent proteins. This action facilitates the proper localization and function of proteins within the cell, underscoring the importance of SEC11A in cellular homeostasis and protein maturation.

THERAPEUTIC SIGNIFICANCE:
Given the fundamental role of SEC11A in protein maturation, exploring its mechanisms offers a promising avenue for the development of novel therapeutic interventions. Targeting SEC11A could provide new strategies for treating conditions associated with defective protein processing and trafficking.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.